Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001628280-22-008988
Filing Date
2022-04-12
Accepted
2022-04-12 16:14:19
Documents
22

Document Format Files

Seq Description Document Type Size
1 424B3 contexttherapeutics424b3-p.htm 424B3 1570829
2 a20220323_pipelineslide.jpg GRAPHIC 458966
3 business10a.jpg GRAPHIC 116945
4 business11a.jpg GRAPHIC 99001
5 business12a.jpg GRAPHIC 169488
6 business13a.jpg GRAPHIC 62470
7 business14a.jpg GRAPHIC 127993
8 business15a.jpg GRAPHIC 101614
9 business16a.jpg GRAPHIC 85739
10 business17a.jpg GRAPHIC 60284
11 business18a.jpg GRAPHIC 68365
12 business19a.jpg GRAPHIC 86317
13 business20a.jpg GRAPHIC 78878
14 business3a.jpg GRAPHIC 124244
15 business4a.jpg GRAPHIC 137918
16 business5a.jpg GRAPHIC 85547
17 business6a.jpg GRAPHIC 49615
18 business7a.jpg GRAPHIC 125917
19 business8a.jpg GRAPHIC 63813
20 business9a.jpg GRAPHIC 127606
21 image_26.jpg GRAPHIC 47702
22 image_5.jpg GRAPHIC 157511
  Complete submission text file 0001628280-22-008988.txt   4855258
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

EIN.: 863738787 | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-261599 | Film No.: 22822420
SIC: 2834 Pharmaceutical Preparations